Tag Archives: biotech industry

Fireside Chat with Moncef Slaoui, GlaxoSmithKline

Dr. Moncel Slaoui

Moncel Slaoui, chairman of research and development (R&D) at GlaxoSmithKline (GSK), opened the 2012 BIO CEO & Investor Conference with a Fireside Chat where he provided insight in to his company’s biopharma R&D strategy. “GSK has announced that our R&D budget is no more a percentage of sales. If you think about it, it doesn’t make sense,” Slaoui stated, “because, sales are a marker of R&D 10 and 15 years ago.” Right now, GSK has Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Managing in a Cost-Constrained Environment

medicine-thumb

By Jill E. Sackman, D.V.M., Ph.D., Senior Consultant, and Matt Levy, J.D., Business Analyst, at Numerof & Associates, Inc. (NAI) The pharmaceutical industry has entered a critical period of transition. Business models that have proven remarkably successful over the past 20 years are now encountering major challenges. As biotech companies grapple with the leading symptoms of these challenges – pricing pressures, pipeline productivity concerns, a growing public distrust, and greater political and regulatory scrutiny – Read More >

Business of Biotech  |  1 Comment  |  Email This Post
Tags: , , , , ,

2012 BIO International Convention to Highlight Breakthroughs

sarah-thumb

2012 BIO International Convention to Highlight Breakthroughs in Healing, Fueling, and Feeding the World The BIO International Convention Program Committee recently selected 125 thought-provoking and timely sessions among 13 educational tracks. The 2012 tracks include: Achieving Regulatory Approval and Compliance; Biofuels and Biobased Chemicals; Biotech Patenting and Tech Transfer; Business Development; Drug Discovery and Development; Finance; Food and Agriculture; Global Innovation and Markets; Health Policy and Reimbursement; Innovations in Vaccines; International Case Studies; Manufacturing of Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Sizing up the NBI in 2011

How did the Nasdaq Biotechnology Index (NBI) perform in 2011 relative to other sectors? Second place. Not so bad considering 2011 was the year of defense in the stock market. Like a page out of a textbook on defensive market plays, utilities edged out ahead with a +15% gain, followed by consumer staples with 11%. The NBI squeezed in between at 12%, just above the overall healthcare sector. Overall, the S&P500 was flat for the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

Biomedical Innovation: How the U.S. Can Stay Number One

lab_tech02-thumb

By Ross DeVol, chief research officer of the Milken Institute “The first step in winning the future is encouraging American innovation,” declared President Obama in his last State of the Union speech. A logical place to start is making sure that where we hold a lead, we keep it. Today, the U.S. has such a lead in biomedical innovation — the process of transforming scientific discoveries into vaccines, diagnostics, devices and therapies that improve and Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,